Log on / register
BioMed Central home | Journals A-Z | Feedback | Support

Comments

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

Shalini L Kulasingam email, Steve Benard email, Ruanne V Barnabas email, Nathalie Largeron email and Evan R Myers email

Cost Effectiveness and Resource Allocation 2008, 6:4doi:10.1186/1478-7547-6-4

No comments have yet been made on this article

Post a comment

© 1999-2008 BioMed Central Ltd unless otherwise stated < info@biomedcentral.com >   Terms and conditions